[The effects of cardiopulmonary bypass on pulmonary surfactant activity]

Zhonghua Jie He He Hu Xi Za Zhi. 1997 Aug;20(4):225-7.
[Article in Chinese]

Abstract

Objective: To study the effects of cardiopulmonary by pass(CPB) on pulmonary surfactant (PS) activity.

Method: In 12 children with patent ductus arteriosus(PDA) and 19 patients with ventricular septal defect (VSD), saturated phosphatidylcholine (SatPC), total phospholipids (TPL), total protein (TP) and surfactant protein-A(SP-A) in sequential airway aspirates before and after operation were determined. Tetroxide osmium digestion and neutral alumina column chromatography were used for SatPC, and a modified immunoblot method with a rabbit anti-human SP-A polyclonal antibody for SP-A measurment.

Results: In 19 VSD patients with CPB, SatPC/TPL was significantly decreased from 48% to 34% (t = 2.737, P < 0.05), SatPC/TP decreased from 64 to 33 mg/g (t = 3.011, P < 0.01), and SP-A from 23 to 11mg/g (t = 2.987, P < 0.01). In 12 patients without CPB, SatPC/TPL, SatPC/TP, SP-A/TP levels were not changed.

Conclusions: CPB significantly reduces pulmonary surfactant activity.

Publication types

  • Comparative Study
  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiopulmonary Bypass* / adverse effects
  • Child
  • Child, Preschool
  • Ductus Arteriosus, Patent / metabolism*
  • Ductus Arteriosus, Patent / surgery
  • Female
  • Heart Septal Defects, Ventricular / metabolism*
  • Heart Septal Defects, Ventricular / surgery
  • Humans
  • Male
  • Phosphatidylcholines / metabolism
  • Phospholipids / metabolism
  • Proteolipids / metabolism
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants / metabolism*

Substances

  • Phosphatidylcholines
  • Phospholipids
  • Proteolipids
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants